Find disease awareness content and relevant supporting materials
Publication in New England Journal of Medicine of results from phase II study of inaxaplin for focal segmental glomerulosclerosis.- Vertex
Vertex Pharmaceuticals Incorporated announced publication in the New England Journal of Medicine (NEJM) of results from preclinical studies and a Phase II study evaluating the efficacy and safety of inaxaplin (VX 147) on top of standard-of-care in people with focal segmental glomerulosclerosis (FSGS) and two APOL1 variants , a severe, rapidly progressive form of chronic kidney disease also known as APOL1-mediated kidney disease (AMKD). AMKD is caused by variants of the APOL1 gene and affects approximately 100,000 people in the U.S. and Europe. Inaxaplin is an APOL1 inhibitor aimed at treating the underlying cause of AMKD.
New analysis of MRI findings show Uplizna reduced the formation of asymptomatic optic nerve lesions in people with neuromyelitis optica spectrum disorder.- Horizon Therapeutics/Amgen
Horizon Therapeutics plc announced the presentation of new MRI imaging data from the Phase III clinical trial showing Uplizna reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with NMOSD. These findings are being presented during the 49th annual meeting of the North American Neuro-Ophthalmology Society (NANOS) March 11-16, 2023, in Orlando, Florida.
Using a Decision Wheel to Reduce Use of Restraints in a Medical-Surgical Intensive Care Unit.
Little information is available on the use of tools in intensive care units to help nurses determine when to restrain a patient. Patients in medical-surgical intensive care units are often restrained...
Tigecycline is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1): Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4); Complicated intra-abdominal infections (cIAI). Tigecycline should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Barriers and Strategies for Early Mobilization of Patients in Intensive Care Units.
Early mobilization of patients in the intensive care unit (ICU) is safe, feasible, and beneficial. However, implementation of early mobility as part of routine clinical care can be challenging. The...
Ontozry 25 mg film-coated tablets ▼
Ontozry is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products.